NASDAQ:ANAB
AnaptysBio Inc Stock News
$23.94
+0.290 (+1.23%)
At Close: May 31, 2024
AnaptysBio-Generated Antibody Scores Second FDA Approval For Solid Tumor Indication
06:59am, Wednesday, 18'th Aug 2021
The FDA has approved a second indication for GlaxoSmithKline plc's (NYSE: GSK) Jemperli (dostarlimab-gxly). The approval comes for adult patients with mismatch repair deficient (dMMR) recurrent or
FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors
04:32pm, Tuesday, 17'th Aug 2021
SAN DIEGO, Aug. 17, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune co
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates
07:13pm, Monday, 09'th Aug 2021
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of 86.67% and 8.87%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio Announces Second Quarter 2021 Financial Results and Provides Pipeline Updates
04:05pm, Monday, 09'th Aug 2021
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune co
AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference
04:15pm, Thursday, 27'th May 2021
SAN DIEGO, May 27, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune con
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Misses Revenue Estimates
06:47pm, Tuesday, 04'th May 2021
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of 7.04% and -1.45%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO, April 23, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune c
Why AnaptysBio Stock Is Attractive After 30% Selloff
03:06pm, Tuesday, 16'th Mar 2021
AnaptysBio Inc's (NASDAQ: ANAB) stock seems attractive after the POPLAR data and the 30% selloff, while there are several catalysts over the next 12-18 months, according to Truist Securities. Anaptys
Why AnaptysBio Stock Is Popping Today
01:50pm, Tuesday, 16'th Mar 2021
This analyst is excited about the company's prospects.
Why AnaptysBio Shares Rose Nearly 14% on Thursday
07:00pm, Thursday, 11'th Mar 2021
A phoenix may well rise from the ashes of a disappointing clinical trial.
Why AnaptysBio Plummeted Today
05:46pm, Monday, 08'th Mar 2021
The company's leading drug candidate failed to meet its primary endpoint in a phase 2 clinical trial.
AnaptysBio: Upcoming Catalyst Seems Like Quite The Gamble
05:20pm, Tuesday, 02'nd Mar 2021
ANAB has a wholly-owned pipeline and partnered pipeline. ANAB has an upcoming catalyst in Q1'21, results from the POPLAR trial of ANB019 in palmoplantar pustulosis.
Why AnaptysBio Was a Stock Market Star on Friday
06:55pm, Friday, 26'th Feb 2021
There was some encouraging news from across the Atlantic.
Why AnaptysBio Fell by as Much as 10% Today
06:41pm, Tuesday, 23'rd Feb 2021
Perhaps no news is bad news for the ambitious biotech.
AnaptysBio, Inc. (ANAB) Earnings Expected to Grow: Should You Buy?
01:41pm, Monday, 22'nd Feb 2021
AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
